| 77 | 0 | 32 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨人β半乳糖苷α-2,6-唾液酸转移酶Ⅰ(ST6GalⅠ)在肾透明细胞癌(ccRCC)癌组织及正常肾组织中表达的差异及其对患者预后的影响。方法以2013年1月-2019年12月来本院就诊的ccRCC患者127例为研究对象。应用qRT-PCR方法检测癌组织及同一患者正常肾脏组织中的ST6GalⅠ表达。分析ST6GalⅠ在癌组织及正常肾脏组织中的表达水平的差异,并收集患者的临床资料,对纳入研究患者通过电话、门诊、住院等方式进行随访患者生存情况。采用Kaplan-Meier生存分析法计算患者生存率。采用Cox比例回归风险模型分析影响患者预后的因素。结果 qRTPCR结果显示,纳入研究的患者癌组织中ST6GalⅠ的表达水平显著高于同一患者正常肾脏组织,差异具有统计学意义(P<0.05);经Kaplan-Meier法分析结果显示,ST6GalⅠ高表达、组织类型为中低分化、肿瘤直径>7 cm,临床分期为Ⅱ期是影响患者生存的因素。经多因素Cox回归分析结果显示,ST6GalⅠ高表达、组织类型为中低分化、肿瘤直径>7 cm、临床分期为Ⅱ期是影响患者预后的独立危险因素。结论 ST6GalⅠ在癌组织中的表达水平显著高于正常肾脏组织,且ST6GalⅠ高表达是患者预后的独立危险因素,同时组织分级为中低分化、肿瘤直径>7 cm、临床分期为Ⅱ期也是患者预后不良的独立危险因素。
Abstract：Objective To investigate the difference of expression of human β-galactoside α-2,6-sialyl-transferase I(ST6 GalI) in clear cell renal carcinoma(ccRCC) and normal renal tissues, and its effect on prognosis of patients.Methods A total of 127 patients with renal clear cell carcinoma who admitted in the hospital from January 2013 to December 2019 were selected as the research objects. The expression of ST6 GalⅠ was detected by qRT-PCR to analyze the difference of ST6 GalI expression level in the cancer tissue and normal kidney tissue, and collect the clinical data of patients, and follow-up the survival of patients. Kaplan-Meier survival analysis was used to calculate the survival rate. Cox proportional regression risk model was used to analyze the prognostic factors. Results The results of qRT-PCR showed that the expression level of ST6 GalI in the cancer tissue was significantly higher than that in the normal kidney tissue(P< 0.05); the Kaplan Meier analysis showed that the high expression of ST6 GalI, the low and medium differentiation of tissue type, tumor volume > 7 cm, clinical stage II were the factors affecting the survival of patients. Multivariate Cox regression analysis showed that the high expression of ST6 GalI, low and medium differentiation of tissue type, tumor volume > 7 cm, clinical stage of stage II were the independent risk factors affecting the prognosis of patients. Conclusion The expression level of ST6 GalI in the cancer tissue is significantly higher than that in the normal kidney tissue, and the high expression of ST6 GalI is an independent risk factor for the prognosis of patients.Meanwhile, the tissue type of low differentiation, tumor volume > 7 cm, clinical stage II are also the independent risk factors for unfavourable prognosis.
[1] BUTZ H, DING Q, NOFECHMOZES R, et al. Elucidating mechanisms of sunitinib resistance in renal cancer:an integrated pathological-molecular analysis[J].Oncotarget,2018,9(4):4661-4674.
[2] KUMAR R, KAPOOR A. Current management of metastatic renal cell carcinoma:evolving new therapies[J].Curr Opin Support Palliat Care,2017,11(3):231-237.
[3]张涛，王玉杰.保留肾单位手术与根治性肾切除术治疗T1a肾癌疗效比较[J].新疆医科大学学报,2012,35(5):634-637.
[4] MAKHOV P,JOSHI S,GHATALIA P,et al.Resistance to systemic therapies in clear cell renal cell carcinoma:Mechanisms and management strategies[J].Mol Cancer Ther,2018,17(7):1355-1364.
[5] LINEHAN W M,RICKETTS C J.The Cancer genome atlas of renal cellcarcinoma:Findingsandclinicalimplications[J]. Nat RevUrol,2019,16(9):539-552.
[6] LUCARELLI G,LOIZZO D,FRANZIN R,et al.Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma[J].Expert Rev Mol Diagn,2019,19(5):397-407.
[7] HSIEH C C,SHYR Y M,LIAO W Y,et al.Elevation ofβ-galactosideα2,6-sialyltransferase 1 in a fructoseresponsive manner promotes ancreatic cancer metastasis[J].Oncotarget,2017,8(5):7691-7709.
[8] GARNHAM R,SCOTT E,LIVERMORE K E,et al.ST6GAL1:A key player in cancer[J].Oncol Lett,2019,18(2):983-989.
[9] CUI H,YANG S,JIANG Y,et al.The glycosyltransferase ST6Gal-I is enriched in cancer stem-like cells in colorectal carcinoma and contributes to theirchemo-resistance[J].Clin Transl Oncol,2018,20(9):1175-1184.
[10] VENTURI G,GOMES F,PUCCI M,et al. Impact of sialyltransferase ST6GAL1 overexpression on different colon cancer celltypes[J].Glycobiology,2019, 29(10):684-695.
[11] YUAN Q,CHEN X,HAN Y,et al. Modification ofα2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway[J]. Int J Cancer,2018,143(9):2319-2330.
[12] WICHERT B,MILDE L K,GALATENKO V, et al.Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer[J]. Glycobiology,2018, 28(11):898-903.
[13] SCHULT MJ,HOLDBROOKS AT,CHAKRABORTY A,et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype[J].Cancer Res,2016,76(13):3978-3988.
[14] LIU N, ZHU M, LIN HY, et al. Increasing HER2α2,6 sialylation facilitates gastric cancer progression and resistance via the akt and erk pathways[J].Oncol Rep,2018,40(5):2997-3005.
[15] JONSE RB, DORSETT KA, HJELMELANG AB, et al.The ST6GalI sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1αsignaling[J].J Biol Chem,2018,293(15):5659-5667.
[16] WEI A,FAN B, ZHAO Y,et al. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway[J]. Oncotarget,2016,7(40):65374-65388.
[17] SHIN B,KRESS RL,KRAMER PA,et al. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation[J]. J Exp Med,2018,215(7):1803-1812.
[18] NASIRIKENARI M, CHANDRASEKARAN EV, MATTA KL, et al.Altered eosinophil profile in mice with ST6Gal-I deficiency:An additional role for ST6Gal-Igenerated by the P1 promoter in regulating allergic inflammation[J]. J Leukoc Biol,2010, 87(3):457-466.
[19]李前进，王玉杰,刘强,等. ST6GalⅠ抑制TNFR1的表达而调控肾透明细胞癌凋亡[J].中国癌症防治杂志，2020,12(4):415-420.
[20]杨建,刘建和,李沛,等.早期肾透明细胞癌的高风险因素及预后分析[J].现代泌尿生殖肿瘤杂志,2019,11(2):76-78.
基本信息:
中图分类号:R737.11
引用信息:
[1]李前进,拜合提亚·阿扎提,王文光,等.ST6GalⅠ在肾透明细胞癌中的表达及其对患者预后的影响[J].新疆医科大学学报,2020,43(12):1531-1534.
基金信息:
国家自然科学基金(81060210);; 新疆维吾尔自治区自然科学基金(2017D01C294)
2021-01-05
2021-01-05
2021-01-05